Hepatitis Monthly

Published by: Kowsar

Association between Serum Cytokeratin-18 Neoepitope M30 (CK-18 M30) Levels and Chronic Hepatitis B: A Meta-Analysis

Changfei Li 1 , Shousheng Liu 2 , 3 , Linlin Lu 2 , 3 , Quanjiang Dong 3 , 4 , Shiying Xuan 1 , 2 , 4 , * and Yongning Xin 1 , 2 , 4 , 5 , **
Authors Information
1 Medical College of Qingdao University, Qingdao 266071, China
2 Digestive Disease Key Laboratory of Qingdao, Qingdao 266071, China
3 Central Laboratories, Qingdao Municipal Hospital, Qingdao 266071, China
4 Department of Gastroenterology, Qingdao Municipal Hospital, Qingdao, Shandong Province, China
5 Department of Infectious Disease, Qingdao Municipal Hospital, Qingdao 266011, China
Corresponding Authors:
Article information
  • Hepatitis Monthly: April 2018, 18 (4); e64152
  • Published Online: April 30, 2018
  • Article Type: Research Article
  • Received: November 17, 2017
  • Accepted: April 20, 2018
  • DOI: 10.5812/hepatmon.64152

To Cite: Li C, Liu S, Lu L, Dong Q, Xuan S, et al. Association between Serum Cytokeratin-18 Neoepitope M30 (CK-18 M30) Levels and Chronic Hepatitis B: A Meta-Analysis, Hepat Mon. 2018 ; 18(4):e64152. doi: 10.5812/hepatmon.64152.

Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004;350(11):1118-29. doi: 10.1056/NEJMra031087. [PubMed: 15014185].
  • 2. Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol. 2017;8(2):229-42. doi: 10.21037/jgo.2017.03.14. [PubMed: 28480063].
  • 3. Bitton Alaluf M, Shlomai A. New therapies for chronic hepatitis B. Liver Int. 2016;36(6):775-82. doi: 10.1111/liv.13086. [PubMed: 26854115].
  • 4. Kang SM, Shin MJ, Kim JH, Oh JW. Proteomic profiling of cellular proteins interacting with the hepatitis C virus core protein. Proteomics. 2005;5(8):2227-37. doi: 10.1002/pmic.200401093. [PubMed: 15846844].
  • 5. Zeng DW, Dong J, Liu YR, Jiang JJ, Zhu YY. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol. 2016;22(29):6663-72. doi: 10.3748/wjg.v22.i29.6663. [PubMed: 27547009].
  • 6. Invernizzi F, Vigano M, Grossi G, Lampertico P. The prognosis and management of inactive HBV carriers. Liver Int. 2016;36 Suppl 1:100-4. doi: 10.1111/liv.13006. [PubMed: 26725905].
  • 7. Branchi F, Conti CB, Baccarin A, Lampertico P, Conte D, Fraquelli M. Non-invasive assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol. 2014;20(40):14568-80. doi: 10.3748/wjg.v20.i40.14568. [PubMed: 25356021].
  • 8. Pan CQ, Zhang JX. Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int J Med Sci. 2005;2(1):36-40. [PubMed: 15968338].
  • 9. Jieanu CF, Ungureanu BS, Sandulescu DL, Gheonea IA, Tudorascu DR, Ciurea ME, et al. Quantification of liver fibrosis in chronic hepatitis B virus infection. J Med Life. 2015;8(3):285-90. [PubMed: 26351528].
  • 10. Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol. 2009;50(1):1-3. doi: 10.1016/j.jhep.2008.10.014. [PubMed: 19017551].
  • 11. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38(6):1449-57. doi: 10.1016/j.hep.2003.09.022. [PubMed: 14647056].
  • 12. Ijaz B, Ahmad W, Javed FT, Gull S, Hassan S. Revised cutoff values of ALT and HBV DNA level can better differentiate HBeAg (-) chronic inactive HBV patients from active carriers. Virol J. 2011;8:86. doi: 10.1186/1743-422X-8-86. [PubMed: 21352567].
  • 13. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-26. doi: 10.1053/jhep.2003.50346. [PubMed: 12883497].
  • 14. Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, DeBruyne R, Dhawan A. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr. 2010;51(4):500-6. doi: 10.1097/MPG.0b013e3181e376be. [PubMed: 20808246].
  • 15. Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Ann Transl Med. 2017;5(3):40. doi: 10.21037/atm.2017.01.28. [PubMed: 28251119].
  • 16. Lee JE, Lee JM, Lee KB, Yoon JH, Shin CI, Han JK, et al. Noninvasive assessment of hepatic fibrosis in patients with chronic hepatitis B viral infection using magnetic resonance elastography. Korean J Radiol. 2014;15(2):210-7. doi: 10.3348/kjr.2014.15.2.210. [PubMed: 24643284].
  • 17. Eren F, Yilmaz Y, Kose S, Ozdemir FT, Yonal O, Kurt R, et al. Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B. Clin Chim Acta. 2010;411(23-24):2029-32. doi: 10.1016/j.cca.2010.08.035. [PubMed: 20807521].
  • 18. Cave M, Falkner KC, Henry L, Costello B, Gregory B, McClain CJ. Serum cytokeratin 18 and cytokine elevations suggest a high prevalence of occupational liver disease in highly exposed elastomer/polymer workers. J Occup Environ Med. 2011;53(10):1128-33. doi: 10.1097/JOM.0b013e31822cfd68. [PubMed: 21915069].
  • 19. Rosso C, Caviglia GP, Abate ML, Vanni E, Mezzabotta L, Touscoz GA, et al. Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. Dig Liver Dis. 2016;48(1):55-61. doi: 10.1016/j.dld.2015.09.008. [PubMed: 26514735].
  • 20. Yang ZH, Yang SX, Qin CZ, Chen YX. Clinical values of elevated serum cytokeratin-18 levels in hepatitis: a meta-analysis. Hepat Mon. 2015;15(5). e25328. doi: 10.5812/hepatmon.15(5)2015.25328. [PubMed: 26045704].
  • 21. Feldstein AE, Alkhouri N, De Vito R, Alisi A, Lopez R, Nobili V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol. 2013;108(9):1526-31. doi: 10.1038/ajg.2013.168. [PubMed: 23752877].
  • 22. Liang J, Liu F, Wang F, Han T, Jing L, Ma Z, et al. A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease. Biomed Res Int. 2017;2017:8793278. doi: 10.1155/2017/8793278. [PubMed: 28349067].
  • 23. Shi J, Ying H, Du J, Shen B. Serum Sclerostin Levels in Patients with Ankylosing Spondylitis and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Biomed Res Int. 2017;2017:9295313. doi: 10.1155/2017/9295313. [PubMed: 28553652].
  • 24. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Chrysanthos N, Georgiou A, Kafiri G, et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut. 2008;57(4):500-6. doi: 10.1136/gut.2007.123943. [PubMed: 18025069].
  • 25. Sumer S, Aktug Demir N, Kolgelier S, Cagkan Inkaya A, Arpaci A, Saltuk Demir L, et al. The Clinical Significance of Serum Apoptotic Cytokeratin 18 Neoepitope M30 (CK-18 M30) and Matrix Metalloproteinase 2 (MMP-2) Levels in Chronic Hepatitis B Patients with Cirrhosis. Hepat Mon. 2013;13(6). e10106. doi: 10.5812/hepatmon.10106. [PubMed: 24032040].
  • 26. Yilmaz B, Aktas B, Altinbas A, Ginis Z, Ozturk G, Ekiz F, et al. The Role of M30 in Predicting the Severity of Liver Fibrosis and Inflammation in Chronic Hepatitis B Patients. Hepat Mon. 2016;16(9). e35640. doi: 10.5812/hepatmon.35640. [PubMed: 27822256].
  • 27. Balkan A, Yilmaz N, Balkan Y, Koruk I, Orkmez M, Aydinli M, et al. Relationship between liver injury and serum cytokeratin 18 levels in asymptomatic hepatitis B virus carriers and in patients with chronic hepatitis B infection. Arab J Gastroenterol. 2017;18(2):98-103. doi: 10.1016/j.ajg.2017.05.008. [PubMed: 28579343].
  • 28. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31(1):11-24. [PubMed: 6186379].
  • 29. Linder S, Olofsson MH, Herrmann R, Ulukaya E. Utilization of cytokeratin-based biomarkers for pharmacodynamic studies. Expert Rev Mol Diagn. 2010;10(3):353-9. doi: 10.1586/erm.10.14. [PubMed: 20370591].
  • 30. Linder S, Havelka AM, Ueno T, Shoshan MC. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett. 2004;214(1):1-9. doi: 10.1016/j.canlet.2004.06.032. [PubMed: 15331168].
  • 31. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50(4):1072-8. doi: 10.1002/hep.23050. [PubMed: 19585618].
  • 32. Aida Y, Abe H, Tomita Y, Nagano T, Seki N, Sugita T, et al. Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease. Int J Clin Exp Med. 2014;7(11):4191-8. [PubMed: 25550930].
  • 33. Chen J, Zhu Y, Zheng Q, Jiang J. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis. Hepatol Res. 2014;44(8):854-62. doi: 10.1111/hepr.12197. [PubMed: 23834322].
  • 34. Swiderska M, Jaroszewicz J, Parfieniuk-Kowerda A, Rogalska-Plonska M, Stawicka A, Panasiuk A, et al. Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease. Mediators Inflamm. 2017;2017:3480234. doi: 10.1155/2017/3480234. [PubMed: 28827897].
  • 35. Oliveira VO, Oliveira JP, Franca EV, Brito HL, Nascimento TV, Franca A. Advanced liver injury in patients with chronic hepatitis b and viral load below 2,000 IU/mL. Rev Inst Med Trop Sao Paulo. 2016;58:65. doi: 10.1590/S1678-9946201658065. [PubMed: 27680170].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments